![]() ![]() Silverstein formerly served as Chief Financial Officer and Principal Financial Offer for Abeona. Prior to her current role, she was the Chief Financial Officer of Emendo Biotherapeutics, a gene editing company (acquired by Anges Inc, a gene-based medicines company in December 2020). Christine serves as Chief Financial Officer at Excision Biotherapeutics, a CRISPR gene-editing company for viral infectious dieseases. in Finance and Healthcare from the Wharton School of the University of Pennsylvania.Ĭhristine Silverstein brings over 15 years of experience in corporate finance and capital markets strategy. in Microbiology, Immunology & Molecular Biology and his post-doc in epigenetics at University of Arizona, and earned his M.B.A. Previously, he was Head of Early-Stage Upstream Process Development for Biologics at Dr. Most recently, he led the team responsible for the launch of Breyanzi® (lisocabtagene maraleucel liso-cel), an autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphoma. ![]() Seshadri served in roles of increasing responsibility at Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company (BMS), where he focused on development and commercialization of novel therapies in hematology and oncology. Seshadri has more than 20 years of experience including academia and various senior and executive leadership roles in the life sciences industry overseeing product development, regulatory submissions, and commercialization for novel therapies including personalized, autologous cell and gene therapies. Vishwas (Vish) Seshadri, Ph.D., M.B.A., joined Abeona as Head of Research & Clinical Development in June 2021 and was appointed President and Chief Executive Officer, and member of the Company’s Board of Directors, in October 2021. in Biological Sciences, summa cum laude, from Rider University.ĭr. in Management from the Stern School of Business, New York University, and his B.A. Amoroso held various marketing and sales leadership positions over his 10-plus year tenure at Sanofi. In this capacity, he helped Celgene develop an organizational model to commercialize cell therapies including specialized manufacturing and customer services for patients with lymphoma and myeloma. Amoroso worked at Celgene for six years in several commercial roles before serving as the organization’s Commercial Lead for CAR T-cell therapy programs. Amoroso was Senior Vice President, Americas for Eisai’s Commercial Oncology Business Group, where he was accountable for teams charged with creating and driving commercial strategy and implementation for the company’s approved products and earlier-stage assets. At Kite, he was responsible for the company’s worldwide commercial organization leading the commercialization efforts for the autologous CAR T-cell therapy, YESCARTA®, and the future cell therapy pipeline. Amoroso held various senior level commercial positions at leading biopharmaceutical companies, including Kite, Eisai Inc., Celgene Corporation (now a subsidiary of Bristol-Myers Squibb Company), and Sanofi. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |